For example, in NSCLC, HMGB3 may act as an oncogene, and its increased expression can indicate poor outcomes for NSCLC patients [219], while suppression of HMGB3 expression by miR-30a-5p improves survival prognosis. Here, HMGB3 is linked to non-small cell lung carcinoma.